Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

JANX 007

Next Previous
Drug Profile

JANX 007

Alternative Names: JANX-007; Prostate specific membrane antigen tumour activated T-cell engager therapy - Janux Therapeutics/Merck & Co; PSMA TRACTr - Janux Therapeutics/Merck & Co

Latest Information Update: 04 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Janux Therapeutics
  • Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Peptides; Recombinant fusion proteins
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 01 Dec 2025 Efficacy data from a phase Ia trial in Prostate cancer released by Janux Therapeutics
  • 28 Oct 2025 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in Australia (IV)
  • 28 Oct 2025 No recent reports of development identified for phase-I development in Prostate-cancer(Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top